Novartis Shares Plunge Nearly 10% Following Clinical Trial Setbacks
Summary
Shares of pharma giant Novartis dropped nearly 10% on Tuesday after disappointing results from clinical trials, including del-desiran.
Prepared by the newsroom with AI assistance; the original link is always provided
Shares of pharmaceutical major Novartis tumbled nearly 10% on Tuesday, heading for their worst single-day drop on record. The sharp decline followed a series of setbacks across three clinical drug trials.
Investor sentiment deteriorated sharply after disappointing results from the company's del-desiran drug trial. The setbacks across multiple research programs have heightened market concerns regarding the company's pipeline development.
Source: CNBC
Read the original →Latest news
Bank CenterCredit Repurchases Shares for 18.2B Tenge on KASE
Bank CenterCredit JSC has repurchased 4.1 million of its common shares on the Kazakhstan Stock Exchange for 18.2 billion tenge.
Source: KASE
Home Credit Bank Bonds Added to KASE T+ List
Starting October 8, Home Credit Bank bonds (KZQ000001213, HCBNe1) will be included in the KASE T+ List.
Source: KASE
KASE Publishes Member Activity Rankings for September 2026
Kazakhstan Stock Exchange has released its exchange member activity rankings for September 2026 on its official website.
Source: KASE
KASE Index rises 0.25% to 7,862.81 points
On October 7, the KASE Index climbed by 0.25% to settle at 7,862.81 points.
Source: KASE